Catherine A. Harwood

Catherine A. Harwood

Auto-generated profile, based on publicly available information

Catherine A. Harwood

Barts Health NHS Trust and Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1998 in Nature
Verified
Journal Article
Closed access
PDF file
ASAlan Storey
Alan Storey
MTMiranda Thomas
Miranda Thomas
AKAnn Kalita
Ann Kalita
CHCatherine Harwood
Catherine Harwood
DGDaniela Gardiol
Daniela Gardiol
LBLawrence Banks
Lawrence Banks

16 September 2005 in Science
Verified
Journal Article
Closed access
PDF file
POPeter O'Donovan
Peter O'Donovan
CPConal M. Perrett
Conal M. Perrett
XZXiaohong Zhang
Xiaohong Zhang
BMBeatriz Montaner
Beatriz Montaner
YXYao Xu
Yao Xu
PKPeter Karran
Peter Karran
Oxidative stress and mutagenic DNA lesions formed by reactive oxygen species (ROS) are linked to human malignancy. Clinical treatments inducing chronic oxidative stress may therefore carry a risk of therapy-related cancer. We suggest that immunosuppression by azathioprine (Aza) may be one such treatment. Aza causes the accumulation of 6-thioguanine (6-TG) in patients' DNA. Here we demonstrate that biologically relevant doses of ultraviolet A (UVA) generate ROS in cultured cells with 6-TG–substituted DNA and that 6-TG and UVA are synergistically mutagenic. A replication-blocking DNA 6-TG photoproduct, guanine sulfonate, was bypassed by error-prone, Y-family DNA polymerases in vitro. A preliminary analysis revealed that in five of five cases, Aza treatment was associated with a selective UVA photosensitivity. These findings may partly explain the prevalence of skin cancer in long-term survivors of organ transplantation.

1 May 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MMMaria Marin
Maria Marin
CJChristine A. Jost
Christine A. Jost
LBLouise A. Brooks
Louise A. Brooks
MIMeredith S. Irwin
Meredith S. Irwin
JOJenny O'NIons
Jenny O'NIons
WKWilliam G. Kaelin
William G. Kaelin

1 July 2000 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
CHCatherine A. Harwood
Catherine A. Harwood
TST. Surentheran
T. Surentheran
JMJane M. McGregor
Jane M. McGregor
PSPatricia J. Spink
Patricia J. Spink
ILIrene M. Leigh
Irene M. Leigh
CPCharlotte M. Proby
Charlotte M. Proby

1 October 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
ASAndrew P. South
Andrew P. South
KPKarin J. Purdie
Karin J. Purdie
SWStephen A. Watt
Stephen A. Watt
SHSam Haldenby
Sam Haldenby
NBNicoline Y. Den Breems
Nicoline Y. Den Breems
ILIrene M. Leigh
Irene M. Leigh

10 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Gareth InmanGareth Inman
Gareth Inman
JWJun Wang
Jun Wang
ANAi Nagano
Ai Nagano
LALudmil B. Alexandrov
Ludmil B. Alexandrov
KPKarin J. Purdie
Karin J. Purdie
ILIrene M. Leigh
Irene M. Leigh
Cutaneous squamous cell carcinoma (cSCC) has a high tumour mutational burden (50 mutations per megabase DNA pair). Here, we combine whole-exome analyses from 40 primary cSCC tumours, comprising 20 well-differentiated and 20 moderately/poorly differentiated tumours, with accompanying clinical data from a longitudinal study of immunosuppressed and immunocompetent patients and integrate this analysis with independent gene expression studies. We identify commonly mutated genes, copy number changes and altered pathways and processes. Comparisons with tumour differentiation status suggest events which may drive disease progression. Mutational signature analysis reveals the presence of a novel signature (signature 32), whose incidence correlates with chronic exposure to the immunosuppressive drug azathioprine. Characterisation of a panel of 15 cSCC tumour-derived cell lines reveals that they accurately reflect the mutational signatures and genomic alterations of primary tumours and provide a valuable resource for the validation of tumour drivers and therapeutic targets.